Concepedia

Delphine Hennicken

DH

Statistics

Publications

14

Citations

2.8K

H-Index

14

Active since

2008

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Belgium)

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Bristol-Myers Squibb (Germany)

Inserm

Delphine Hennicken is an author at Bristol-Myers Squibb (United States) specializing in medicine, cancer therapeutics, and oncology.

Top concepts

Publications per year

2008–2022

14

Publications

14

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

David R. Nelson, James N. Cooper, Jacob Lalezari et al. · Hepatology · 2015 · 688 citations · Full text

The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder

Ronald N. Marcus, Robert D. McQuade, William H. Carson et al. · Journal of Clinical Psychopharmacology · 2008 · 514 citations

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert et al. · The Lancet Oncology · 2017 · 483 citations

, , +8

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

Clifford J. Bailey, J. L. Gross, Delphine Hennicken et al. · BMC Medicine · 2013 · 355 citations · Full text

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

Robert R. Henry, Alexander V. Murray, Marisol Herrera Marmolejo et al. · International Journal of Clinical Practice · 2012 · 309 citations

1–5 of 14